Results 221 to 230 of about 106,022 (294)

Corrigendum to: The Short and Sweet on Sodium-Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure. [PDF]

US Cardiol
Batista JL, Makuvire T, Davis JD, Carbone S.   +3 more
europepmc   +1 more source

Real‐World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim In December 2022, semaglutide injections for weight management were marketed in Denmark. Pre‐marketing trials documented high efficacy when adherence to the treatment and the recommended dose titration schedule was followed. This study aimed to describe real‐world use of semaglutide, including dose titration, discontinuation patterns and ...
Mie Dyberg Skandov, Katrine McLain Christensen, Dagmar Abelone Dalin, Janne Unkerskov, Andreas Brønden, Marie Lund, Mikkel Bring Christensen, Kristian Karstoft   +7 more
wiley   +1 more source

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Lykke Ida Kaas Oldenburg, Sine Pfeiffer Haugaard, Tobias Karlsson, Victoria Kegel‐Hübner, Mahera Parwez, Christoffer Wiingaard, Anne Flint   +6 more
wiley   +1 more source

Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

Rev Cardiovasc Med
West L, Patolia H, Chapman B, Laffin L, Vest AR, Sauer AJ, Martyn T.   +6 more
europepmc   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control. [PDF]

Pharmaceuticals (Basel)
Xanthopoulou M, Evangelidis P, Poulis D, Gavriilaki E, Kotsiou N, Antza C, Kotsis V, Doxani C, Mprotsis T, Zintzaras E, Anyfanti P.   +10 more
europepmc   +1 more source

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists Following Bariatric Surgery: A Systematic Review and Meta-Analysis. [PDF]

Endocrinol Diabetes Metab
Bilal AR, Ibrahim M, Arfin SMW, Bilal AR, Balach R, Qureshi S, Gaba H, Collins P, Ahmed R, Waqas SA.   +9 more
europepmc   +1 more source

The Benefits and Risks of Glucagon-Like Peptide-1 Receptor Agonists on Ocular Diseases: A Narrative Review. [PDF]

Cureus
Huang JXF, Wu J, Ahmad H, Li J, Joshi S, Yousaf A, Pemminati R, Pemminati S.   +7 more
europepmc   +1 more source

Perioperative risks of glucagon-like peptide-1 receptor agonists and their implications in airway management using supraglottic airway devices. [PDF]

Anesth Pain Med (Seoul)
Oh CS, Lee S, Hong B.
europepmc   +1 more source

Gallbladder‐Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo‐Controlled STEP Trials

Diabetes, Obesity and Metabolism, EarlyView.
Mika Ukkonen, Antti Kivivuori, Peter Starckjohann, Pekka Lammi, Anna Junttila, Valtteri Panula   +5 more
wiley   +1 more source